Understanding the Market | MicroPort Medbot-B rose over 5%, and the commercialization process of TuMai has entered a stage of full acceleration, with overseas orders exceeding 60 units
I'm PortAI, I can summarize articles.
MicroPort Medbot-B's stock price rose by more than 5%, reaching HKD 30.2, with a transaction volume of HKD 130 million. According to the announcement, as of now, the order volume for core products in endoscopy, orthopedics, and vascular intervention has exceeded 170 units, among which the global commercialization orders for the Tumai endoscopic surgical robot have surpassed 100 units, and overseas orders have exceeded 60 units, covering nearly 40 countries and regions, accelerating the commercialization process
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments